Skip to content
Calculator
Analysis

GLP-1s and the brain: alcohol, addiction and dementia in 2026

Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board

Intricate MRI brain scan displayed on a computer screen for medical analysis and diagnosis
Photo by MART PRODUCTION on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Alcohol: small randomised trials have reported. Three semaglutide trials found less heavy or per-occasion drinking, an exenatide trial missed its main goal, and a 2025 review adds a dulaglutide trial that lowered intake in current drinkers. Promising, but no GLP-1 drug is approved for alcohol use disorder.
  • Dementia: the large evoke and evoke+ trials of semaglutide in 3,808 people with early Alzheimer's disease found no slowing of decline over two years, and a liraglutide trial missed its main goal too.
  • The striking numbers from huge observational studies, which link these drugs to less addiction and dementia, show associations, not proof. The Alzheimer's trials are the clearest example of why that distinction matters.

Why anyone thought GLP-1s might work in the brain

Preclinical, observational and pharmacoepidemiology evidence suggested that GLP-1 drugs may reduce alcohol intake 1; exenatide, for example, reduces alcohol consumption in rodents and nonhuman primates 2. For dementia, the evoke investigators cite animal, clinical and real-world studies in people with type 2 diabetes or obesity suggesting a lower risk of dementia and Alzheimer's disease after GLP-1 drug exposure 3, and liraglutide had shown neuroprotective effects in animal models 4. That is what led to trials in Alzheimer's disease.

Then came very large observational studies. A Veterans Affairs analysis compared 215,970 people with diabetes who started a GLP-1 drug with people starting other diabetes drugs or continuing usual care, across 175 health outcomes. Compared with usual care, GLP-1 use was associated with lower risks of substance use disorders, psychotic disorders and neurocognitive disorders including Alzheimer's disease and dementia, alongside higher risks of gastrointestinal disorders, low blood pressure, kidney stones and drug-induced pancreatitis 5. The authors present the atlas as a guide for clinical care and research agendas 5; associations of this kind are tested by randomised trials.

Alcohol: what the trials show

Four randomised, placebo-controlled trials of GLP-1 drugs in alcohol use disorder (AUD) are summarised below 2 1 6 7. They are not the only ones: a 2025 systematic review also counted a dulaglutide trial 8.

TrialWhoPrimary resultNotable secondary results
Exenatide, 26 weeks (2022)127 treatment-seeking adults with AUDNo reduction in heavy drinking daysLess brain reactivity to alcohol cues; fewer heavy drinking days in the subgroup with obesity
Semaglutide, low dose, 9 weeks (2025)48 adults with AUD, not seeking treatmentLess alcohol drunk in a laboratory taskFewer drinks per drinking day and less craving; no change in drinking days
Oral semaglutide, 8 weeks (2026)50 treatment-seeking adults with moderate to severe AUDNo reduction in laboratory cue-induced cravingFewer heavy drinking days and drinks per drinking day; less day-to-day craving and cannabis use
Semaglutide, phase 2 (2026)108 treatment-seeking adults with AUD and obesityHeavy drinking days fell 41.1 points vs 26.4 on placebo (difference 13.7)Gastrointestinal side effects more common

The pattern is consistent enough to take seriously. The semaglutide trials, in different populations and with different main outcomes, all found reductions in heavier drinking: fewer drinks on drinking days, fewer heavy drinking days, or less alcohol consumed in a controlled setting 1 6 7. The largest, in 108 people with AUD and obesity, met its primary outcome, with heavy drinking days falling about 14 percentage points more than on placebo 7. A 2025 systematic review of the earlier randomised trials reached a similar reading: semaglutide reduced alcohol use, dulaglutide lowered intake in current drinkers, and exenatide had no significant effect on heavy drinking days 8.

The cautions are just as important. These trials are small, short (8 to 26 weeks) and mostly phase 2; two missed their primary outcome and found effects only in secondary measures 2 6. The exenatide trial's benefit appeared only in an exploratory subgroup with obesity 2, and the largest semaglutide trial enrolled only people with obesity 7, so whether the effect holds in lean people with AUD is unclear. Larger trials are needed before any GLP-1 drug could be approved for alcohol use disorder, and none is approved today.

How a GLP-1 drug might change drinking

The exenatide trial gave the clearest look at mechanism, even though it missed its main goal. In participants who had brain scans, exenatide reduced the response to alcohol cues in the ventral striatum and septal area, regions central to reward and craving, and dopamine transporter availability was lower than on placebo 2. The low-dose semaglutide trial found less alcohol drunk and lower peak breath-alcohol in a laboratory session where participants could choose how much to drink, alongside less craving week to week 1. Gastrointestinal side effects were more frequent on semaglutide in the largest trial 7, and none of these abstracts reports a test of how much of the drop in drinking those side effects explain.

What the alcohol trials still need to answer

Several practical questions remain open. The trials ran for 8 to 26 weeks 2 1 6 7, so they cannot show whether the effect lasts, or whether drinking rebounds when the drug stops. Most participants were women in one trial and people with obesity in another 1 7, so effects in other groups are uncertain. All four compared a GLP-1 drug with placebo; none compared it with naltrexone, acamprosate or disulfiram, the three FDA-approved medicines for AUD 9, or tested a combination. And the size of the benefit in the largest trial, about 14 percentage points fewer heavy drinking days than placebo, is meaningful but not dramatic 7. The 2025 review's conclusion was that large randomised trials are needed 8.

Smoking, cannabis and other substances

The evidence for other substances is thinner still. In the 2025 semaglutide trial, a subgroup of participants who smoked cut their cigarettes per day more than those on placebo 1, and the 2026 oral semaglutide trial found fewer cannabis use days 6. Both were secondary findings in small groups, the kind of signal that justifies a dedicated trial rather than a conclusion. The Veterans Affairs cohort's association with lower risk of substance use disorders covers several substances at once and cannot separate cause from the many differences between people prescribed different diabetes drugs 5. Until dedicated trials report, claims that GLP-1 drugs treat addiction go beyond the evidence.

Dementia: the trials that said no

Alzheimer's disease is where the observational hope met its sternest test. The evoke and evoke+ phase 3 trials randomised 3,808 people with early symptomatic Alzheimer's disease, average age 72, to oral semaglutide or placebo for 104 weeks. Decline on the Clinical Dementia Rating Sum of Boxes, the main measure, was essentially identical: an increase of 2.3 and 2.2 points on semaglutide against 2.3 and 2.1 on placebo, with no significant difference in either trial 3. Adverse events were more common on semaglutide (91.2% against 84.8%) 3. The investigators' conclusion was plain: oral semaglutide was not efficacious in slowing clinical progression 3.

The liraglutide trial ELAD, in 204 people with mild to moderate Alzheimer's disease without diabetes, also missed its primary outcome, a change in brain glucose metabolism on PET scans. One executive-function measure favoured liraglutide, but daily activities and the overall dementia rating did not differ 4. Neither trial found a GLP-1 drug slowing Alzheimer's disease once symptoms had begun 3 4. Whether these drugs might lower the risk of developing dementia, as the cohorts suggest, is a different question that these trials did not test.

It is worth being precise about what evoke tested: oral semaglutide at up to 14 mg a day, flexibly dosed, in people aged 55 to 85 with amyloid-confirmed mild cognitive impairment or mild dementia due to Alzheimer's disease 3. It did not test injected semaglutide at weight-loss doses or people without symptoms, and only 2.8% of evoke+ participants had significant small vessel pathology 3. Those gaps leave room for future trials, but they do not rescue the original hope that these drugs could treat Alzheimer's disease.

Why the cohorts and the trials disagree

The gap between the observational studies and the Alzheimer's trials is a lesson in reading evidence. People prescribed GLP-1 drugs can differ from people prescribed other diabetes drugs in ways a records study does not fully capture, and statistical adjustment can only correct for differences that were measured. The drugs also cause weight loss and better blood sugar control, which could lower dementia risk without any direct effect on the brain. And a cohort that looks at risk of a first diagnosis asks a different question from a trial that treats people who already have symptoms.

None of this makes the cohort findings worthless; they point to where trials should look. It means a headline that a drug 'cuts dementia risk' based on records data should be read as 'is associated with', until a randomised trial says otherwise. Our guide to reading a study explains why the rung of the evidence ladder matters.

Mood and psychiatric safety

The brain effects of GLP-1 drugs are a safety question as well as a hope. The Wegovy and Zepbound labels used to carry a warning about suicidal behaviour and ideation; both labels list that warning as removed in February 2026 10 11. The Veterans Affairs atlas found lower, not higher, risks of substance use and psychotic disorders with GLP-1 use, while also listing increased risks such as gastrointestinal disorders and drug-induced pancreatitis 5. Removal of a label warning is not a guarantee for any individual: anyone who notices new or worsening low mood, anxiety or suicidal thoughts on any medicine should contact their prescriber promptly.

What this means now

For alcohol, the evidence is the most encouraging of any brain-related use, but it is early. Alcohol use disorder has three FDA-approved medicines, disulfiram, naltrexone and acamprosate 9; a GLP-1 drug should not be started for drinking outside a trial or a careful discussion with a doctor. For people already taking a GLP-1 drug for diabetes or weight, any reduction in drinking is a welcome side effect, not a treatment plan.

For dementia, the large trials have answered the main question: semaglutide does not slow early Alzheimer's disease 3. For other substances, the data are signals. As of October 27, 2026, no GLP-1 drug is approved for any addiction or for dementia 12, and that includes research or compounded versions sold for these purposes. Our GLP-1 transition hub covers the approved uses.

Frequently asked questions

Does Ozempic reduce alcohol cravings?

Small randomised trials of semaglutide in alcohol use disorder found reductions in heavy drinking, drinks per drinking day or craving, but they were short and phase 2. No GLP-1 drug is approved for alcohol use disorder.

Does semaglutide prevent dementia?

It has not been shown to. The evoke and evoke+ trials found oral semaglutide did not slow decline in 3,808 people with early Alzheimer's disease. Observational studies link GLP-1 use with lower dementia risk, but that is an association, not proof.

Can GLP-1 drugs treat addiction?

Not yet. The evidence for alcohol is promising but early, and for smoking, cannabis and other drugs it comes from secondary findings in small trials and observational studies. A 2025 review concluded that large randomised trials are needed.

Why did the Alzheimer's trials fail when cohort studies looked good?

Cohorts compare people who differ in many ways besides the drug, and they ask about developing dementia rather than slowing it once symptoms start. Randomised trials remove those differences, and in Alzheimer's disease they found no benefit.

Sources

  1. Hendershot, C. S., et al. (2025). Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 82(4), 395-405. PMID: 39937469
  2. Klausen, M. K., et al. (2022). Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight, 7(19). PMID: 36066977
  3. Cummings, J. L., et al. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet, 407(10544), 2167-2179. PMID: 41865758
  4. Edison, P., et al. (2026). Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial. Nat Med, 32(1), 353-361. PMID: 41326666
  5. Xie, Y., et al. (2025). Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med, 31(3), 951-962. PMID: 39833406
  6. Schacht, J. P., et al. (2026). Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial. Am J Psychiatry, 183(9), 636-645. PMID: 42522065
  7. Klausen, M. K., et al. (2026). Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet, 407(10540), 1687-1698. PMID: 42070571
  8. Patel, S., et al. (2025). GLP-1 receptor agonists and alcohol use disorder: a systematic review. Alcohol Alcohol, 61(1). PMID: 41273789
  9. National Institute on Alcohol Abuse and Alcoholism. Medications Development Program: "Currently, there are three Food and Drug Administration (FDA)-approved medications for the treatment of AUD" (disulfiram, naltrexone, acamprosate). Page last reviewed October 2021; read October 27, 2026.
  10. Novo Nordisk. Wegovy (semaglutide) US prescribing information, Recent Major Changes (Suicidal Behavior and Ideation warning removed 02/2026) (DailyMed set ee06186f, version 19, effective June 18, 2026); Recent Major Changes re-read on DailyMed October 27, 2026. DailyMed
  11. Eli Lilly. Zepbound (tirzepatide) US prescribing information, Recent Major Changes (Suicidal Behavior and Ideation warning removed 02/2026) (DailyMed set 487cd7e7, version 40, effective August 28, 2026); Recent Major Changes re-read on DailyMed October 27, 2026. DailyMed
  12. Grey Peptides encyclopedia: approved indications for semaglutide, liraglutide, exenatide and tirzepatide, from their labels and Drugs@FDA. Read October 27, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead